Literature DB >> 12001005

6-thioguanine in the treatment of psoriasis: a case report and literature review.

Daniel W Sherer1, Mark G Lebwohl.   

Abstract

BACKGROUND: 6-Thioguanine is a purine analog primarily indicated for acute myelogenous leukemia. Its use in psoriasis was first investigated in the 1950s and current interest in serious treatments for psoriasis, such as cyclosporine, has renewed interest in this medication. Newer therapies, such as PUVA and retinoids, have side effects as do some older treatments, such as methotrexate, which fell into favor at the same time 6-thioguanine was being investigated. Reexamining older treatments can open up new therapeutic options in difficult cases.
OBJECTIVE: The goal of this article is to provide a comprehensive review of the literature regarding the use of 6-thioguanine in the treatment of psoriasis as well as an illustrative case report demonstrating the use and side effects of 6-thioguanine in a patient with pustular psoriasis. Topics reviewed include efficacy, side effects, laboratory monitoring, different dosing regimens, and proposed mechanisms of action.
CONCLUSIONS: 6-Thioguanine has been highly effective in treating and maintaining improvement in patients with psoriasis. A study comparing efficacies with methotrexate would be extremely useful. Because of the possibility of severe bone marrow depression, 6-thioguanine is not a first-line treatment. However, with new dosing regimens, proper laboratory monitoring, and further studies, use of 6-Thioguanine could expand in the future.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12001005     DOI: 10.1007/s10227-001-0140-8

Source DB:  PubMed          Journal:  J Cutan Med Surg        ISSN: 1203-4754            Impact factor:   2.092


  2 in total

1.  New Nanomedicine Approaches Using Gold-thioguanine Nanoconjugates as Metallo-ligands.

Authors:  Lee Sleightholm; Ajit Zambre; Nripen Chanda; Zahra Afrasiabi; Kattesh Katti; Raghuraman Kannan
Journal:  Inorganica Chim Acta       Date:  2011-06-15       Impact factor: 2.545

2.  A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2.

Authors:  Bruce E Strober; Jennifer Clay Cather; David Cohen; Jeffrey J Crowley; Kenneth B Gordon; Alice B Gottlieb; Arthur F Kavanaugh; Neil J Korman; Gerald G Krueger; Craig L Leonardi; Sergio Schwartzman; Jeffrey M Sobell; Gary E Solomon; Melodie Young
Journal:  Dermatol Ther (Heidelb)       Date:  2012-03-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.